Yogliptin monotherapy in type 2 diabetes: A 12-week randomized, double-blind, placebo-controlled phase II study.

Xin WangYing WangXiaolan YongBojun WuZiling SunNing LouQing WenYufang ZhangShiyun LiJiarui LiYan HeJinluo ChengXiangdong ZhongJing ShenWenying Yang

Published in: Journal of diabetes (2022)

This study demonstrated that yogliptin controlled glycemia in Chinese T2DM cases, with a great safety profile. The current findings supported that any of the three doses of yogliptin, administered once a week, could be used for phase III clinical studies.

Keyphrases

placebo controlled
phase iii
phase ii study
double blind
type diabetes
phase ii
open label
clinical trial
study protocol
glycemic control
combination therapy
insulin resistance
adipose tissue
metabolic syndrome